Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 202 UK small molecule drug companies below.
AI-driven robotic chemistry platform for on-demand molecule synthesis
Chemify is a UK deep-tech company that digitises chemical synthesis by combining a proprietary chemistry programming language, robotics, and artificial intelligence. Its platform…
Tau-targeting therapeutics and diagnostics for neurodegenerative disease
TauRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments and diagnostics for Alzheimer's disease and related neurodegenerative disorders. Its…
Bioanalytical CRO supporting drug development from discovery to post-marketing
York Bioanalytical Solutions is a contract research organisation providing bioanalytical, metabolism and biomarker services to pharmaceutical and biotech companies. The company…
Automated drug discovery platform and CRO services
Arctoris is a technology-enabled contract research organisation that provides automated wet-lab biology and data generation services to biotech and pharmaceutical companies. The…
CRO-CDMO process chemistry and API manufacturing centre for global pharma partners
Sai Life Sciences operates a UK research and development site providing contract research and development and manufacturing services to global biotech and pharmaceutical…
Non-surgical drug therapy for spinal cord injury recovery
NeuroSolv Therapeutics is a preclinical-stage biotechnology company developing a non-surgical two-part therapy for spinal cord injury. The proposed mechanism combines enzymatic…
Topical formulations treating atopic dermatitis and inflammatory skin disease
Quodria is a dermatology-focused biotech developing novel topical formulations for skin diseases using nanotechnology-enabled drug delivery. Its lead programme, Q001, is a small…
Implantable localised chemotherapy delivery for hard-to-treat solid tumours
CRISM Therapeutics is a clinical-stage drug delivery company developing an implantable biodegradable technology that delivers chemotherapy directly into tumours or surgical…
Non-invasive small molecule eye drops for retinal vascular disease
Foventa is a biopharmaceutical company developing non-invasive, small molecule therapeutics for retinal vascular diseases that can cause vision loss. Its lead candidate targets…
Epigenetic reprogramming and senolytic therapeutics for cancer and ageing
199 Biotechnologies is a preclinical-stage biotechnology company developing epigenetic reprogramming and senolytic therapies targeting cancer and age-related disease. Its lead…
Clinical-stage therapeutics for oncology and behavioural brain disorders
TheraCryf is a clinical-stage drug development company developing small-molecule therapeutics for oncology and behavioural brain disorders. Its lead oncology candidate, derived…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company…